Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […]
In precision oncology, tissue quality plays a pivotal role in maintaining data integrity. We explore the impact of standardizing tissue collection and processing on data quality, and how this helps enhance patient outcomes as well as our understanding of cancer. Insights from tissue samples play an important role across the drug life cycle – from […]
Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […]
Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]
There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that has become dysregulated in almost […]
This week, our guest on the podcast is Jason C. Foster, CEO of Ori Biotech. Ori is a London, U.K. and New Jersey, U.S. based manufacturing technology company pioneering flexible process discovery with translation and scalable commercialization of cell and gene therapies (CGT), increasing access to these innovative treatments. Ori has developed a proprietary, full […]
In most cases, chronic inflammation is known to lead to cancer, however, the mechanisms behind this are not fully understood. Preclinical models in immuno-oncology are the first step towards a better understanding of cancer mechanisms, improved treatments and prevention of cancer caused by inflammation. Inflammation is the immune system’s natural response to bacterial, viral, and […]
Emerging as a new class of drugs, radiopharmaceuticals are all the rage in cancer treatment research, at present. And now, with American biotech Nucleus RadioPharma raising $56 million to streamline its supply chains and make the drugs more accessible, it seems like the radiopharmaceutical market might be onto something big. The series A funding round, […]
Currently considered an incurable disease, there is a lot of work being done around developing better treatment options for metastatic breast cancer, and, ultimately, a cure. Numerous promising candidates are in clinical trials, all with the hope of progressing toward U.S. Food and Drug Administration (FDA) approval. According to the World Health Organization (WHO), 2.3 […]
This week, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell […]
The immune system protects our bodies from foreign invaders, but sometimes, when it malfunctions, it can result in life-threatening autoimmune disorders. But what if the immune system could be regulated to counter these diseases? Immunometabolism, an emerging field in therapeutics, aims to rein in autoimmunity altogether. According to Neil Weir, chief executive officer (CEO) of […]